Regulation of immune functions in rat splenocytes after acute and chronic in vivo treatment with CP-55,940, a synthetic cannabinoid compound

被引:23
作者
Patrini, G [1 ]
Sacerdote, P [1 ]
Fuzio, D [1 ]
Manfredi, B [1 ]
Parolaro, D [1 ]
机构
[1] UNIV MILAN, SCH MED, DEPT PHARMACOL, I-20129 MILAN, ITALY
关键词
CP-55,940; SR141716A; splenocyte proliferation; natural killer cytotoxicity;
D O I
10.1016/S0165-5728(97)00149-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Changes in mitogen-induced splenocyte proliferation and NK activity were evaluated after acute (1 h) and chronic (6 d) in vivo treatment of rats with the synthetic cannabinoid compound CP-55,940. At a dose of 0.4 mg/kg i.p. it significantly inhibited the splenocyte proliferative response to PHA and NK activity but half this dose (0.2 mg/kg) had no effect on immune responses. Pretreatment of rats with the cannabinoid receptor CB1 antagonist SR141716A did not antagonize the CP-55,940-induced immunosuppression, excluding the activation of this receptor subtype in the mediation of this effect. When immune function studies were done on rats tolerant to CP-55,940-induced analgesia, full tolerance also developed for the inhibition of splenocyte proliferation and NK activity. The data provided indicate that CB1 cannabinoid receptors are not involved in mediating the acute and chronic effects of cannabinoids on the immune system and suggest a possible implication of CB2 receptor although other modalities of CP-55,940 action can not be ruled out. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:143 / 148
页数:6
相关论文
共 33 条
[1]  
[Anonymous], LIFE SCI
[2]   INVITRO AND INVIVO SUPPRESSIVE EFFECTS OF DELTA-9-TETRAHYDROCANNABINOL ON INTERFERON-PRODUCTION BY MURINE SPLEEN-CELLS [J].
BLANCHARD, DK ;
NEWTON, C ;
KLEIN, TW ;
STEWART, WE ;
FRIEDMAN, H .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1986, 8 (07) :819-824
[3]  
CABRAL GA, 1991, ADV EXP MED BIOL, V288, P93
[4]  
CABRAL GA, 1993, ADV BIOSCI, V86, P653
[5]  
Compton DR, 1996, J PHARMACOL EXP THER, V277, P586
[6]  
D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74
[7]   Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception [J].
Edsall, SA ;
Knapp, RJ ;
Vanderah, TW ;
Roeske, WR ;
Consroe, P ;
Yamamura, HI .
NEUROREPORT, 1996, 7 (02) :593-596
[8]   EXPRESSION OF CENTRAL AND PERIPHERAL CANNABINOID RECEPTORS IN HUMAN IMMUNE TISSUES AND LEUKOCYTE SUBPOPULATIONS [J].
GALIEGUE, S ;
MARY, S ;
MARCHAND, J ;
DUSSOSSOY, D ;
CARRIERE, D ;
CARAYON, P ;
BOUABOULA, M ;
SHIRE, D ;
LEFUR, G ;
CASELLAS, P .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1995, 232 (01) :54-61
[9]   Immune regulation by cannabinoid compounds through the inhibition of the cyclic AMP signaling cascade and altered gene expression [J].
Kaminski, NE .
BIOCHEMICAL PHARMACOLOGY, 1996, 52 (08) :1133-1140
[10]  
KAMINSKI NE, 1992, MOL PHARMACOL, V42, P736